Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 2 - Jan. 12, 2018
Issue 1 - Jan. 5, 2018
  • ASCO forms collaboration with two Big Data firms to grow CancerLinQ

    The ten-year collaboration, announced Dec. 21, gives Tempus and PH.AI access to de-identified data from over a growing database of more than a million records contained in CancerLinQ.

    ASCO and its new commercial partners will continue to expand CancerLinQ and, at the same time, look for better ways to aggregate and mine the data. The data could be used in drug development as well as scientific projects and quality initiatives.

  • Conversation with the Cancer Letter

    Hudis: ASCO needed collaborators to help CancerLinQ deliver faster on its mission

    “This is a licensure and a strategic collaboration. This leverages the expertise of several organizations to allow us to deliver real value to our members and subscribers faster than we would have been able to otherwise.”

  • Conversation with the Cancer Letter

    Lefkofsky: CancerLinQ has value in ushering in an era of precision medicine

    “This gets a bit into Tempus’s business model and at least how we view the world. This data has some commercial applicability today. But the real value in this data is in how do you build much larger, much more comprehensive datasets that actually can be used to usher in an era of precision medicine.”

  • Introducing the clinical section of The Cancer Letter

    Today’s issue of The Cancer Letter contains a new section devoted to clinical news.

    As part of our new format, stories that have immediate clinical significance will appear in every issue, much like a sports or business section in a newspaper.

  • An Appreciation

    Jimmie Holland, founder of psycho-oncology, dies at 89

    Jimmie C. Holland, internationally recognized as the founder of the field of psycho-oncology, died suddenly on Dec. 24, 2017, at the age of 89.

  • An Appreciation

    Gerald Hanks, pioneering radiation oncologist, dies at 83

    Gerald E. Hanks was a giant in the world of radiation oncology and oncology in general. It isn’t often that we can say this and probably understate a person’s significance and influence, but Jerry was one of those people.  He died on Dec. 20, 2017, at the age of 83.

  • In Brief

    • Howard “Skip” Burris elected ASCO president for 2019-2020
    • Hochster named associate director, clinical research, and chief of GI med/onc at Rutgers
    • Whitten named president of Taiho Oncology
    • Purdue Center for Cancer Research receives $10 million from Walther Cancer Foundation
    • METAvivor announces 2017 grant awards for metastatic cancer research
    • JAX starts canine cancer initiative to find predictors, treatments for humans, dog
  • TCCL Logo

  • Trials and Tribulations

    Cabozantinib in first-line treatment of metastatic renal cell carcinoma

    Systemic therapies for metastatic renal cell carcinoma (mRCC) have expanded dramatically over the past 3 years.

  • Clinical Roundup

    • CAP publishes guideline to ensure accurate HPV testing in head and neck cancers
    • CAR-T therapy cancer study published in the New England Journal of Medicine
    • Cancer mortality in the U.S. continues decades-long drop
  • Drugs and Targets

    • FDA approves Perjeta in adjuvant breast cancer
    • FDA approves Cabometyx for previously untreated advanced renal cell carcinoma
    • FDA approves Pfizer’s Bosulif (bosutinib) for newly-diagnosed Ph+ CML
    • FDA approves Xgeva for prevention of skeletal-related events in multiple myeloma
    • Kisqali receives breakthrough designation for HR+/HER2- breast cancer
    • FDA accepts sBLA, grants priority review for Adcetris
    • FDA grants breakthrough designation for Avelumab in combination with Inlyta in RCC
    • FDA grants orphan drug designation to Aptose Biosciences for CG’806 in AML
    • FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated NSCLC
    • FDA grants priority review for Apalutamide in non-metastatic castration-resistant prostate cancer
    • Janssen and Legend Biotech enter deal to develop CAR-T therapy
December 2017PDF

 

Breast Cancer

Pfizer’s talazoparib extends PFS in phase III trial in metastatic breast cancer

The phase III EMBRACA trial in patients with germline BRCA1/2-positive locally advanced and/or metastatic breast cancer demonstrated superior progression-free survival in patients treated with talazoparib, compared to patients who received physician’s choice standard of care chemotherapy.

 

Lymphoma

Juno Therapeutics and Celgene release additional data from TRANSCEND trial

Juno Therapeutics Inc., a biopharmaceutical company developing cellular immunotherapies for the treatment of cancer, released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in a presentation at the 59th American Society of Hematology Annual Meeting and Exposition.

 

Leukemia

Phase III study of venetoclax in combination with rituximab meets primary endpoint

MURANO, a randomized phase III study sponsored by Abbvie, showed that patients with relapsed or refractory chronic lymphocytic leukemia achieved significantly prolonged median progression-free survival with Venclexta/Venclyxto (venetoclax) in combination with Rituxan (rituximab) [median PFS, not reached], compared with bendamustine in combination with Rituxan [median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.11–0.25; P<0.0001].

 

Kidney Cancer

Genentech’s Tecentriq and Avastin reduce the risk of disease worsening or death from RCC

 

Skin Cancer

PD-1 antibody cemiplimab demonstrates 46.3% ORR in advanced cutaneous squamous cell carcinoma

 

Head and Neck Cancer

Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

 

Lung Cancer

Aggressive surgery is best treatment option for early stage lung cancer

 

Side Effects

Daily oral edoxaban met primary endpoint in Hokusai-VTE cancer study

 

Liquid Biopsy

Liquid biopsy results differed substantially between two providers in a study

 

NCI CTEP-Approved Trials for December

  
CCL Dec 2017 - Dec. 29, 2017